Prof. Hermann Luebbert, PhD, serves as the Chief Executive Officer for Biofrontera, Inc. He studied biology in his native city of Cologne, where he completed a PhD in 1984. After eight years of academic research at the University of Cologne and the California Institute of Technology (USA), he was awarded the habilitation at the ETH (Eidgenössische Technische Hochschule) Zürich. Prof. Lübbert has held the Chair of Animal Physiology at Ruhr-University Bochum since 1998. During his ten years at Sandoz and Novartis Pharma AG, Prof. Lübbert acquired experience in managing a globally active research organisation. In 1997, he founded the German Biofrontera AG, which he headed as CEO until December 2021.
John J. Borer III, J.D. became a member of our board of directors in November 2021. Since 2012, he has been the Senior Managing Director and Co-Head of Investment Banking at The Benchmark Company, LLC. He was formerly the Chief Executive Officer and Head of Investment Banking at Rodman & Renshaw, and has held senior positions at Security Pacific Business Credit and Barclays American Business Credit. Mr. Borer has also served on the Supervisory Board of Biofrontera AG from May 2016 to December 2021. He holds a Doctor of Law degree (J.D.) from Loyola Law School in Los Angeles, California and a degree in Agricultural Economics from The University of California, Davis.
Dr. Hoffman is the founder, and, since 2015, has been the President and Chief Executive Officer, of Origami Therapeutics, Inc., in San Diego, California. Dr. Hoffman has over 20 years of experience in drug discovery and development. Dr. Hoffman has made major contributions to the launch of two first-in-class drugs and two best-in-class drugs for Cystic Fibrosis. Beth holds her Ph.D. in Biology from The Johns Hopkins University in Baltimore, Maryland.
Dr. Heikki Lanckriet joind the Board of Directors in July 2023. He was appointed to the Board upon the nomination of Biofrontera AG, a significant stockholder of the Company.
Dr. Lanckriet has over 20 years commercial & scientific experience in life sciences and has a track record of developing high growth technology businesses. Dr. Lanckriet has published scientific papers and is named inventor on a multitude of patents and has broad expertise and commercial experience in the life science area. He has a passion for science and innovation as well as strong commercial pragmatism. Dr. Lanckriet is currently the Chief Executive Officer of 4basebio PLC, Cambridge, United Kingdom, which is listed on the Alternative Investment Market (AIM) of the London Stock Exchange (LSE).
He is also a member of the Supervisory Boards of Biofrontera AG, Leverkusen, Germany, and Epigenomics AG, Berlin, Germany and a member of comparable domestic and foreign control committees of the following commercial enterprises: 4basebio UK Ltd and 4basebio Discovery Limited, both Cambridge, United Kingdom; 4basebio SLU, Madrid, Spain; I2I Capital Limited, Cambridge, United Kingdom; KITHER BIOTECH S.R.L., Turin, Italy; and NeoPhore Ltd, Cambridge.
He holds a Bachelor’s and Master’s degree in Biochemical Engineering from the University of Ghent, Belgium and a PhD in Biochemical Engineering from the University of Cambridge, UK., United Kingdom.
Mr. Weber has been a member of our board of directors since 2022. He is a Principal at Skysis, LLC, a firm that provides commercial strategy consulting services to pharmaceutical, biotech and medical device companies. Prior to Skysis, LLC, he served as Chief Executive Officer of Paraffin International Inc. Prior to Paraffin, Mr. Weber served in senior executive and marketing roles at Depomed, Hyperion Therapeutics and Medicis Pharmaceuticals. Mr. Weber is also a board member of the American Chronic Pain Association and holds a B.S. in Management and Marketing from Western Michigan University.